Abstract
Nineteen adult volunteers were given 50 000 units of human fibroblast interferon intradermally and suffered no adverse reactions apart from short-lived stinging and mild erythema persisting at 24 h. When compared with a control, the interferon protected 13 out of 19 volunteers against vaccinia virus, a statistically significant result ( P = 0·012).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
